JHOP - February 2021 Vol 11, No 1

June 2020 Vol 10, No 3

Optimizing Daratumumab Infusion: Assessing the Safety and Feasibility of Omitting Preinfusion Medications and Decreasing Infusion Time

JHOP - February 2021 Vol 11, No 1 - Retrospective Analysis

Justine Preedit, PharmD; Anya Yudchyts, PharmD, BCOP

Optimizing Response to Enasidenib with Dose Escalation in Relapsed or Refractory Acute Myeloid Leukemia

JHOP - February 2021 Vol 11, No 1 - Case Reports

Amany R. Keruakous, MD; Sarah A. Schmidt, PharmD; Marcus T. Autry, PharmD; Julia Ye, PharmD Candidate; Phoi Nguyen, PharmD Candidate; Silas Day

Concise Reviews of Studies Relevant to Hematology Oncology Pharmacy

JHOP - February 2021 Vol 11, No 1 - From the Literature

With commentaries by Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA

Electrolyte Abnormalities and the Associated Risk for Atrial Fibrillation After Autologous Hematopoietic Stem-Cell Transplant

JHOP - February 2021 Vol 11, No 1 - Original Research

Natalie Schulze, PharmD; Kyle LaPorte, PharmD; Carol Breikreutz, PharmD, BCOP; Tobias Meissner, PhD; R. Vinod Parameswaran, MD, FRCPath, MRCP; Renju Raj, MD; Kelly McCaul, MD, ABIM, FRCPC

Evaluation of Infusion-Related and Hypersensitivity Reactions to Chemotherapy Over a Decade at a Community Cancer Center

JHOP - February 2021 Vol 11, No 1 - Original Research

Sarah Maryon Hayes, PharmD, BCOP; Jeremy Whalen, PharmD, BCOP; Nick Schutz, PharmD; Joseph Levine, MD

Olanzapine versus Fosaprepitant for Chemotherapy-Induced Nausea and Vomiting Prophylaxis in Patients Receiving Single-Day High-Dose Melphalan

JHOP - February 2021 Vol 11, No 1 - Original Research

Ekim Ekinci, PharmD, MS, BCOP; James E. Cox, PharmD, BCOP; Joe E. Ensor, PhD; Edward T. McLean, PharmD, BCOP; Carlos A. Ramos, MD; Premal D. Lulla, MD; Rammurti T. Kamble, MD; George Carrum, MD

Pevonedistat plus Azacitidine Improves Outcomes versus Azacitidine Monotherapy in High-Risk MDS

JHOP - February 2021 Vol 11, No 1 - ASH 2020 Highlights

Ruxolitinib in Graft-versus-Host Disease: Practice-Changing Results

JHOP - February 2021 Vol 11, No 1 - ASH 2020 Highlights

Step-Up Glofitamab Dosing Induces High Response Rates in Relapsed or Refractory Non-Hodgkin Lymphoma

JHOP - February 2021 Vol 11, No 1 - ASH 2020 Highlights

ZUMA-12: Axicabtagene Ciloleucel Shows Substantial Benefit in High-Risk Large B-Cell Lymphoma

JHOP - February 2021 Vol 11, No 1 - ASH 2020 Highlights

Page 1 of 2
Results 1 - 10 of 13